Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therus Corp.

www.therus.com

Latest From Therus Corp.

Renal Denervation Sparks Device Market Gold Rush

With the recent success of Ardian’s Symplicity Renal Denervation System, drug-resistant hypertension has emerged as something of a device market “gold rush.” Some observers estimate there are now as many as 40 companies developing various device-based therapies for resistant hypertension, including most of the big names in the cardiovascular device arena – Medtronic, St. Jude Medical, Boston Scientific, Johnson & Johnson, and Covidien PLC – along with a number of start-ups, all of which are racing to stake a claim in this highly promising market. Only time will tell which companies will be successful – even Medtronic, the first player, has yet to complete its sham-controlled US trial. But the technology’s early promise, along with the sheer size of the opportunity and the acute unmet need, clearly have peaked the interest of investors, manufacturers, and physicians alike, all of whom are chasing after what one participant has called “the next biggest thing in cardiology.”

Medical Device Innovation

Vascular Access Closure Ten Years Later: Why Start-Ups Can't Seal the Deal

Despite the best intentions and brightest innovation, start-ups haven't been able to tap into the huge potential presented by the vascular closure market. Ten years after the first generation devices made it to market, the original two leaders still dominate despite the limitations of their devices, while many start-ups have come and gone. A long list of new hopefuls believe they have the solution physicians have desired. Now all they have to do is convince the physicians, who, when it comes to vascular closure devices, are slow to recognize clinical data but quick to embrace a device that feels right to them.
Medical Device Platform Technologies

What's Hot in Cardiology beyond DES? Try Structural Heart Disease

Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.
Medical Device Innovation

Celleration Inc.

There are four pillars of chronic wound care, and few products address all of them satisfactorily. The four factors encouraging wound healing include debridement, bacterial management, increased blood circulation, and the stimulation of healthy cells. Celleration believes it has all four requirements covered with its MIST Therapy System ultrasound device for wound healing.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Therus Corp.
  • Senior Management
  • David M Perozek, Chmn. & Pres.
    Alex de Soto, VP., Fin. & Admin.
  • Contact Info
  • Therus Corp.
    Phone: (206) 832-4601
    2401 Fourth Ave.
    Suite 200
    Seattle, WA 98121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register